MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
EyePoint Pharmaceuticals Total Shareholders Equity 2011-2026 | EYPT
Annual Total Shareholders Equity EyePoint Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 306 M | 337 M | 266 M | 96.4 M | 184 M | 18.5 M | 8.33 M | 37.6 M | 13.3 M | 20.9 M | 23.4 M | 14.9 M | 7.7 M | 13.6 M | 37.4 M | 33 M | 23.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 337 M | 7.7 M | 84.8 M |
Quarterly Total Shareholders Equity EyePoint Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 230 M | 200 M | 246 M | 298 M | 337 M | 219 M | 228 M | 250 M | 266 M | 58.6 M | 57.3 M | 78.4 M | 96.4 M | 136 M | 151 M | 167 M | 184 M | 92.7 M | 107 M | 116 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 8.33 M | 8.33 M | 8.33 M | 8.33 M | 37.6 M | 37.6 M | 37.6 M | 37.6 M | 9.9 M | 9 M | 9.9 M | 9 M | 14.8 M | 14.3 M | 14.8 M | 14.4 M | 14.4 M | 18.8 M | 14.4 M | 18.8 M | 32.3 M | 35.8 M | 32.3 M | 14.9 M | 12.6 M | 14.2 M | 7.7 M | 7.7 M | 13.8 M | 16.2 M | 13.6 M | 13.6 M | 17.8 M | 35.2 M | 37.4 M | 37.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 337 M | 7.7 M | 71.4 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
5.1 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
24.3 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
351 M | - | - | $ 2.18 B | USA |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-3.89 M | - | -13.47 % | $ 169 M | France |
 |
Alpine Immune Sciences
ALPN
|
328 M | - | - | $ 2.17 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-13.3 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
AstraZeneca PLC
AZN
|
48.7 B | - | - | $ 96.9 B |  Britain |
 |
CureVac N.V.
CVAC
|
697 M | - | - | $ 867 M | Germany |
 |
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | USA |
 |
Coherus BioSciences
CHRS
|
61 M | $ 1.38 | -3.17 % | $ 162 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-14.6 M | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
727 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
3.97 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
11.4 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
57.8 M | - | -34.95 % | $ 21.5 M | Germany |
 |
CRISPR Therapeutics AG
CRSP
|
1.92 B | $ 49.96 | -2.95 % | $ 4.49 B |  Schweiz |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
4.32 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
527 M | $ 29.46 | -0.47 % | $ 1.96 B | USA |
 |
Generation Bio Co.
GBIO
|
86.2 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-6.6 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |
|
Enlivex Therapeutics Ltd.
ENLV
|
1.93 B | $ 0.7 | 0.75 % | $ 32 M | Israel |
 |
Esperion Therapeutics
ESPR
|
-302 M | $ 3.15 | 0.16 % | $ 655 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
6.84 M | - | -4.36 % | $ 27 M | USA |
 |
Eton Pharmaceuticals
ETON
|
26.2 M | $ 31.58 | 3.44 % | $ 850 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
52.4 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
1.38 B | - | - | $ 3.37 B | China |
 |
Exelixis
EXEL
|
2.16 B | $ 52.92 | -0.13 % | $ 14.4 B | USA |
 |
Anika Therapeutics
ANIK
|
143 M | $ 14.97 | 2.75 % | $ 215 M | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
|
Forte Biosciences
FBRX
|
61 M | $ 17.03 | 0.18 % | $ 221 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 2.91 | - | $ 4.79 M | Israel |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |